vs
Side-by-side financial comparison of ARGENX SE (ARGX) and Cellectis S.A. (CLLS). Click either name above to swap in a different company.
ARGENX SE is the larger business by last-quarter revenue ($2.5B vs $9.5M, roughly 260.3× Cellectis S.A.). ARGENX SE runs the higher net margin — 35.5% vs -265.9%, a 301.4% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs 83.2%). ARGENX SE produced more free cash flow last quarter ($322.4M vs $27.6M).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
ARGX vs CLLS — Head-to-Head
Income Statement — Q4 2025 vs Q2 2024
| Metric | | |
|---|---|---|
| Revenue | $2.5B | $9.5M |
| Net Profit | $877.2M | $-25.3M |
| Gross Margin | 89.5% | — |
| Operating Margin | 28.9% | -181.1% |
| Net Margin | 35.5% | -265.9% |
| Revenue YoY | 83.2% | 375.0% |
| Net Profit YoY | 1.3% | -51.9% |
| EPS (diluted) | $13.25 | $-0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5B | — | ||
| Q2 25 | $1.8B | — | ||
| Q4 24 | $1.4B | — | ||
| Q2 24 | $901.9M | $9.5M | ||
| Q3 23 | — | $1.6M | ||
| Q2 23 | $510.9M | $2.0M | ||
| Q2 22 | $116.7M | $2.7M |
| Q4 25 | $877.2M | — | ||
| Q2 25 | $414.8M | — | ||
| Q4 24 | $865.6M | — | ||
| Q2 24 | $-32.5M | $-25.3M | ||
| Q3 23 | — | $-17.5M | ||
| Q2 23 | $-123.2M | $-16.6M | ||
| Q2 22 | $-435.9M | $-19.5M |
| Q4 25 | 89.5% | — | ||
| Q2 25 | 89.2% | — | ||
| Q4 24 | 90.2% | — | ||
| Q2 24 | 89.4% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 91.7% | 97.3% | ||
| Q2 22 | 94.5% | 87.9% |
| Q4 25 | 28.9% | — | ||
| Q2 25 | 19.2% | — | ||
| Q4 24 | 8.7% | — | ||
| Q2 24 | -15.4% | -181.1% | ||
| Q3 23 | — | -1258.1% | ||
| Q2 23 | -40.3% | -1180.5% | ||
| Q2 22 | -340.5% | -1003.0% |
| Q4 25 | 35.5% | — | ||
| Q2 25 | 23.4% | — | ||
| Q4 24 | 64.1% | — | ||
| Q2 24 | -3.6% | -265.9% | ||
| Q3 23 | — | -1064.1% | ||
| Q2 23 | -24.1% | -831.6% | ||
| Q2 22 | -373.7% | -714.4% |
| Q4 25 | $13.25 | — | ||
| Q2 25 | $6.32 | — | ||
| Q4 24 | $13.33 | — | ||
| Q2 24 | $-0.55 | $-0.28 | ||
| Q3 23 | — | $-0.31 | ||
| Q2 23 | $-2.21 | $-0.20 | ||
| Q2 22 | $-8.16 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.5B | $149.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.3B | $148.6M |
| Total Assets | $8.7B | $407.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q4 24 | $1.5B | — | ||
| Q2 24 | $1.4B | $149.0M | ||
| Q3 23 | — | — | ||
| Q2 23 | $1.1B | $84.4M | ||
| Q2 22 | $1.4B | $129.4M |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | $11.0M | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q4 25 | $7.3B | — | ||
| Q2 25 | $6.1B | — | ||
| Q4 24 | $5.5B | — | ||
| Q2 24 | $4.3B | $148.6M | ||
| Q3 23 | — | $76.1M | ||
| Q2 23 | $2.9B | $96.6M | ||
| Q2 22 | $3.0B | $180.5M |
| Q4 25 | $8.7B | — | ||
| Q2 25 | $7.2B | — | ||
| Q4 24 | $6.2B | — | ||
| Q2 24 | $4.8B | $407.1M | ||
| Q3 23 | — | $209.7M | ||
| Q2 23 | $3.2B | $227.7M | ||
| Q2 22 | $3.2B | $320.9M |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $323.3M | $28.9M |
| Free Cash FlowOCF − Capex | $322.4M | $27.6M |
| FCF MarginFCF / Revenue | 13.0% | 290.5% |
| Capex IntensityCapex / Revenue | 0.0% | 13.2% |
| Cash ConversionOCF / Net Profit | 0.37× | — |
| TTM Free Cash FlowTrailing 4 quarters | $594.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $323.3M | — | ||
| Q2 25 | $361.8M | — | ||
| Q4 24 | $41.9M | — | ||
| Q2 24 | $-124.7M | $28.9M | ||
| Q3 23 | — | — | ||
| Q2 23 | $-285.4M | $-47.4M | ||
| Q2 22 | $-494.5M | $-60.2M |
| Q4 25 | $322.4M | — | ||
| Q2 25 | $356.6M | — | ||
| Q4 24 | $40.9M | — | ||
| Q2 24 | $-125.5M | $27.6M | ||
| Q3 23 | — | — | ||
| Q2 23 | $-285.9M | $-47.9M | ||
| Q2 22 | $-494.7M | $-61.7M |
| Q4 25 | 13.0% | — | ||
| Q2 25 | 20.1% | — | ||
| Q4 24 | 3.0% | — | ||
| Q2 24 | -13.9% | 290.5% | ||
| Q3 23 | — | — | ||
| Q2 23 | -56.0% | -2391.4% | ||
| Q2 22 | -424.0% | -2266.7% |
| Q4 25 | 0.0% | — | ||
| Q2 25 | 0.3% | — | ||
| Q4 24 | 0.1% | — | ||
| Q2 24 | 0.1% | 13.2% | ||
| Q3 23 | — | — | ||
| Q2 23 | 0.1% | 24.1% | ||
| Q2 22 | 0.2% | 56.6% |
| Q4 25 | 0.37× | — | ||
| Q2 25 | 0.87× | — | ||
| Q4 24 | 0.05× | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
